Oral therapy for small cell lung cancer

Area of Science:

• Oncology
• Pharmacology
• Clinical Medicine

Background:

• Small cell lung cancer (SCLC) historically had a poor prognosis, with initial improvements seen with simple therapies like cyclophosphamide.
• Current combination chemotherapy results for SCLC have plateaued, necessitating a re-evaluation of treatment strategies for patients without curative potential.

Purpose of the Study:

• To review orally available drugs with known activity against SCLC.
• To explore the potential role of simple oral therapy in improving patient quality of life and reducing hospital visits.
• To assess the utility of oral agents in evaluating new chemotherapy concepts like prolonged administration and dose-intensity.

Main Methods:

• Systematic review of existing literature on oral chemotherapeutic agents for SCLC.
• Analysis of the efficacy and tolerability of oral etoposide as a successful example.
• Discussion of other oral agents, including cyclophosphamide and hexamethylmelamine, for future investigation.

Main Results:

• Oral etoposide has demonstrated success as an oral therapy for SCLC.
• Oral chemotherapy may offer a less burdensome treatment option, potentially enhancing patient quality of life.
• Oral drugs facilitate simpler evaluation of novel chemotherapy strategies, such as prolonged treatment schedules and dose-intensity adjustments.

Conclusions:

• Oral chemotherapy warrants reconsideration for SCLC patients not candidates for curative treatment.
• Agents like oral etoposide, cyclophosphamide, and hexamethylmelamine represent promising avenues for less intensive SCLC management.
• The use of oral drugs simplifies the testing of innovative chemotherapy concepts in SCLC research.